Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

p>

Net loss for the year is expected to be approximately $56 million, or approximately $2.10 per share. Non-cash charges for 2008, consisting primarily of stock-based compensation expense and depreciation and amortization, are expected to total approximately $16.5 million. The total cash balance at December 31, 2008 is expected to be approximately $44 million.

Fourth quarter cash expenditures, consisting primarily of administrative overhead, personnel costs, costs to complete ongoing carcinogenicity studies, costs to complete stability studies for iloperidone, regulatory consulting fees, and commercial discontinuation costs, are expected to total approximately $7.5 million. To reduce expenses, Vanda has taken the following actions:
-- Reduced headcount from 52 full-time employees as of June 30, 2008 to 44

full-time employees as of October 30, 2008. In addition, Vanda has

eliminated four full-time contract commercial positions.

-- Discontinued all commercial activities.

-- Suspended all non-essential manufacturing and pre-clinical activities.

As a result of these initiatives, Vanda expects its operating cash burn to decrease to approximated $3.6 million per quarter beginning in the first quarter of 2009. These expenditures will consist primarily of administrative overhead, personnel costs, costs to complete an ongoing carcinogenicity study and regulatory consulting fees.

Vanda is also evaluating its development pipeline and a number of options to further reduce expenses and cash burn. Vanda will provide additional guidance as soon as its plans are more definitive.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... orbit and the National Aeronautics and Space Administrations (NASA) ... the Earths environment to help predict and prevent infectious ... remote sensing technology aids specialists in predicting the outbreak ... diseases today such as Ebola, West Nile virus and ...
... work of the National Nanotechnology Initiative has just been ... (NSET) Subcommittee of the National Science and Technology Councils ... Coordination Office (NNCO). The 2007 NNI Strategic ... NNI to ensure that the United States derives growing ...
... Robert F. Johnston Named Executive Chairman of the Board ... S. Colin Neill Named President, ISELIN, ... changes in its Board of Directors,and Management, effective immediately., Board Changes, ... Chairman., Haim Aviv, Ph.D., David Schlachet and Mony Ben Dor have ...
Cached Biology Technology:NASA technology helps predict and prevent future pandemic outbreaks 2National Nanotechnology Initiative releases new strategic plan 2National Nanotechnology Initiative releases new strategic plan 3Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Spanish . , Biopesticides containing beneficial ... but U.S. Department of Agriculture (USDA) scientists have shown ... approach, dubbed "liquid culture fermentation," offers several benefits, including ... of insect-killing fungi, including Isaria or ...
... therapy clinical trial in the world for Fabry disease, a rare ... have it by as much as 40 years. Researchers ... patient,s blood. Then a working copy of a new gene will ... During the final phase of the trial, researchers hope to transplant ...
... found the first ancient remains of a calcified ovarian teratoma, in ... era. The find confirms the presence in antiquity of this type ... which are difficult to locate during the examination of ancient remains. ... of bone were found., Teratomas are usually benign and contain remains ...
Cached Biology News:New, cost-cutting approach to formulating pest-killing fungi 2Canada launches first gene therapy trial for Fabry disease 2Canada launches first gene therapy trial for Fabry disease 3Ovarian tumor, with teeth and a bone fragment inside, found in a Roman-age skeleton 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... FL ATP-Gamma-S binds to ATP-binding proteins. ... BODIPY FL fluorophore was linked through ... to its potential use for binding ... is an important new substrate for ...
... standard microarray image analysis software because of ... tools, visualizations, automation capabilities, performance and ease ... every GenePix scanner, and it also imports ... types of arrays. A wide range of ...
Biology Products: